Gordon, MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group: The Ocular Hypertension Treatment Study: Design and baseline description of the participants. Arch Ophthalmol 117:573-583, 1999.

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma.  Arch Ophthalmol 120:701-713, 2002.

Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol 2002; 120:714-720.

Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004; 122:813-820.

The Ocular Hypertension Treatment Study Group (OHTS) and the European Glaucoma Prevention Study Group (EGPS). A Validated Prediction Model for the Development of Primary Open Angle Glaucoma in Individuals with Ocular Hypertension. Ophthalmology. In Press.

European Glaucoma Prevention Study (EGPS) Group.The European Glaucoma Prevention Study design and baseline description of the participants. Ophthalmology 2002; 109: 1612-21.

European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005; 112: 366-375.

European Glaucoma Prevention Study (EGPS) Group. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. In Press.